MusclePharm (MSLPQ) 10-Q/A 13 Jan 14 2013 Q2 Quarterly report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2013	Aug. 13, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'MusclePharm Corp	'
Entity Central Index Key	'0001415684	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'MSLP	'
Entity Common Stock, Shares Outstanding	'	10,127,124
Document Type	'10-Q	'
Amendment Flag	'true	'
Document Period End Date	30-Jun-13	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2013	'
Amendment Description	'The sole purpose of this Amendment No. 1 (this “Amendment”) to MusclePharm Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2013, filed with the Securities and Exchange Commission on August 14, 2013 (the “Form 10-Q”), is to correct an error in the calculation of sales concentration by customer for the six months Ended June 30, 2012 in Note 2 of the Consolidated Financial Statements.  Specifically, Note 2, Subsection “Revenue Recognition” was revised to indicate that the percent of sales for the three largest customers for the three and six months ended June 30, 2013 was as follows: Three Months Ended June 30,   Customer 2013 2012 A 25 % 33 % B 11 % 8 % C 6 % 1 % Six Months Ended June 30, Customer 2013 2012 A 29 % 40 % B 11 % 11 % C 6 % 17 % The previously disclosed calculation for the three largest customers for the six months ended June 30, 2013 was 31%, 12%, and 6%, respectively. While customers A and B remained the same for the three months and six months ended basis, customer C changed for the three months ended June 30, 2012. The calculations are based on gross customer sales as a percent of gross sales for the applicable period. No other modifications or changes have been made to the Form 10-Q. This Amendment speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10-Q.	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2013	Dec. 31, 2012
Assets	'	'
Cash	$8,655,761	$0
Cash - restricted	0	9,148
Accounts receivable - net	9,235,094	3,302,344
Inventory	1,168,348	257,975
Prepaid giveaways	101,680	358,800
Prepaid stock compensation	1,109,313	44,748
Prepaid sponsorship fees	581,877	6,249
Deferred equity costs	0	698,500
Other assets	896,671	272,117
Total current assets	21,748,744	4,949,881
Property and equipment - net	1,329,047	1,356,364
Debt issue costs - net	0	335,433
Other assets	172,994	125,049
Total Assets	23,250,785	6,766,727
Liabilities and Stockholders' Equity	'	'
Accounts payable and accrued liabilities	8,173,356	11,721,205
Customer deposits	24,773	336,211
Debt - net	74,329	4,463,040
Derivative liabilities	2,369,032	0
Total current liabilities	10,641,490	16,520,456
Long Term Liabilities:	'	'
Debt - net	0	4,523
Total Liabilities	10,641,490	16,524,979
Commitments and Contingencies	'	'
Stockholders' Equity:	'	'
Common Stock, $0.001 par value; 100,000,000 shares authorized, 7,766,759 and 2,778,404 issued and 7,716,838 and 2,747,308 outstanding	7,767	2,778
Treasury Stock, at cost; 49,921 and 31,096 shares	-564,515	-460,978
Additional paid-in capital	87,061,004	54,817,341
Accumulated deficit	-73,893,265	-64,109,476
Accumulated other comprehensive loss	-1,841	-7,917
Total Stockholders’ Equity	12,609,295	-9,758,252
Total Liabilities and Stockholders’ Equity	23,250,785	6,766,727
Series A Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Preferred Stock	0	0
Series B Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Preferred Stock	0	0
Series C Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Preferred Stock	0	0
Series D Convertible Preferred Stock [Member]	'	'
Stockholders' Equity:	'	'
Preferred Stock	$145	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
			Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	'	'	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	'	'	5,000,000	5,000,000	51	51	500	500	1,600,000	1,600,000
Preferred stock, shares issued	'	'	0	0	51	51	190	0	1,500,000	0
Preferred stock, shares outstanding	'	'	0	0	51	51	190	0	145,000	0
Common Stock, par value (in dollars per share)	$0.00	$0.00	'	'	'	'	'	'	'	'
Common Stock, shares authorized	100,000,000	100,000,000	'	'	'	'	'	'	'	'
Common Stock, shares issued	7,766,759	2,778,404	'	'	'	'	'	'	'	'
Common Stock, shares outstanding	7,716,838	2,747,308	'	'	'	'	'	'	'	'
Treasury Stock, shares	49,921	31,096	'	'	'	'	'	'	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Sales - gross	$28,515,483	$18,869,103	$53,439,519	$38,171,872
Discounts and sales allowances	-3,035,424	-3,439,763	-5,398,293	-6,181,852
Sales - net	25,480,059	15,429,340	48,041,226	31,990,020
Cost of sales	17,566,718	12,942,605	31,963,124	25,837,767
Gross profit	7,913,341	2,486,735	16,078,102	6,152,253
General and administrative expenses	10,654,272	4,151,076	19,540,512	8,543,887
Income (loss) from operations	-2,740,931	-1,664,341	-3,462,410	-2,391,634
Other income (expense)	'	'	'	'
Derivative expense	0	-1,029,541	-96,913	-2,486,451
Change in fair value of derivative liabilities	272,681	9,854,045	-5,771,963	1,496,874
Gain (loss) on settlement of accounts payable and debt	47,671	0	324,656	-2,941,826
Interest expense	-1,125	-976,686	-781,445	-3,547,202
Foreign currency transaction loss	-104	-1,573	-5,714	-1,573
Other income	0	0	10,000	18,423
Total other income (expense) - net	319,123	7,846,245	-6,321,379	-7,461,755
Net income (loss)	-2,421,808	6,181,904	-9,783,789	-9,853,389
Other comprehensive income	'	'	'	'
Net change in Foreign currency translation	4,228	40,719	-1,841	40,719
Total other comprehensive income (loss)	4,228	40,719	-1,841	40,719
Total comprehensive income (loss)	($2,417,580)	$6,222,623	($9,785,630)	($9,812,670)
Net income (loss) per share available to common stockholders - basic and diluted (in dollars per share)	($0.34)	$3.78	($1.72)	($6.44)
Weighted average number of common shares outstanding during the period - basic and diluted (in shares)	7,226,849	1,633,676	5,686,323	1,530,850

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash Flows From Operating Activities:	'	'
Net loss	($9,783,789)	($9,853,389)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:	'	'
Depreciation	333,383	199,750
Bad debt	105,271	9,490
Amortization of prepaid stock and deferred compensation	3,419,698	456,903
Amortization of debt discount	0	3,083,437
Amortization of debt issue costs	335,433	184,031
Derivative expense	96,913	2,486,451
Change in fair value of derivative liabilities	5,771,963	-1,496,874
Changes in operating assets and liabilities:	'	'
Restricted cash balance	9,148	-52,744
Accounts receivable	-5,713,366	502,193
Prepaid and other	-1,242,246	186,725
Inventory	86,866	-219,276
Increase (decrease) in:	'	'
Accounts payable and accrued liabilities	2,052,010	867,058
Customer deposits	-311,438	1,142,426
Net Cash (Used In) Provided by Operating Activities	-5,164,810	438,007
Cash Flows From Investing Activities:	'	'
Purchase of property and equipment	-307,760	-544,859
Proceeds from disposal of property and equipment	1,694	0
Purchase of trademark	-47,500	-35,000
Net Cash Used In Investing Activities	-353,566	-579,859
Cash Flows From Financing Activities:	'	'
Proceeds from issuance of debt	0	4,073,950
Debt issue costs	0	-106,950
Repayment of debt	-4,393,234	-4,058,442
Repurchase of common stock (treasury stock)	-103,537	-460,978
Proceeds from issuance of preferred stock	12,000,000	0
Proceeds from issuance of common stock and warrants	8,327,499	285,760
Stock issuance costs	-1,662,667	0
Net Cash Provided by (Used In) Financing Activities	14,168,061	-266,660
Cash Flows From Equity Activities:	'	'
Effect of exchange rates on cash and cash equivalents	6,076	40,719
Net Cash Provided by Equity Activities	6,076	40,719
Net increase (decrease) in cash	8,655,761	-367,793
Cash at beginning of period	0	659,764
Cash at end of period	8,655,761	291,971
Supplemental disclosures of cash flow information:	'	'
Cash paid for interest	410,502	265,078
Cash paid for taxes	0	0
Supplemental disclosure of non-cash investing and financing activities:	'	'
Stock issued for future services - third parties	4,409,897	200,000
Warrants issued in conjunction with equity issuances	8,175,459	427,759
Debt discount recorded on convertible and unsecured debt accounted for as a derivative liability	0	3,554,672
Stock issued to settle accounts payable and accrued expenses - third parties	5,484,947	4,667,764
Conversion of convertible debt and accrued interest for common stock	0	1,069,402
Stock issued for executive and board compensation	114,912	0
Reclassification of derivative liability to additional paid in capital	0	4,124,387
Stock issued to settle accrued liabilities	0	135,000
Stock issued to settle contracts	0	3,932
Conversion Of Series C Preferred Stock [Member]	'	'
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:	'	'
(Gain) loss on settlement of accounts payable, debt and conversion of Series C preferred stock	($324,656)	$2,941,826

Nature_of_Operations_and_Basis

Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Note 1: Nature of Operations and Basis of Presentation
	Nature of Operations
	MusclePharm Corporation (the “Company”, “we”, “our”, or “MusclePharm”), was incorporated in the state of Nevada on August 4, 2006 under the name Tone in Twenty for the purpose of engaging in the business of providing personal fitness training using isometric techniques. The Company is headquartered in Denver, Colorado.
	MusclePharm currently manufactures and markets a wide-ranging variety of high-quality sports nutrition products.
	Basis of Presentation
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), as amended for interim financial information.
	The financial information as of December 31, 2012 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 and filed with the SEC on April 1, 2013. The unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K, which contains the audited financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the years ended December 31, 2012 and 2011.
	Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the six months ended June 30, 2013 are not necessarily indicative of results for the full fiscal year.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2: Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiary MusclePharm Canada Enterprises Corp (“MusclePharm Canada”). MusclePharm Canada began operations in April of 2012. All intercompany accounts and transactions between MusclePharm Corporation and MusclePharm Canada have been eliminated upon consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
	Making estimates requires management to exercise significant judgment. It is reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.
	Risks and Uncertainties
	The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, industry adverse publicity and other risks, including the potential risk of business failure.
	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. At June 30, 2013 and December 31, 2012, respectively, the Company had no cash equivalents.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. Prior to July 1, the accounts receivable were sent directly to the Company’s third party manufacturer and netted with any outstanding liabilities to the manufacturer (see Note 11). Liabilities to the manufacturer totaled $4,213,394 at June 30, 2013 and are included in accounts payable and accrued liabilities. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet received by quarter end.
	Management reserves for bad debt expense based on the aging of accounts receivable. Bad debt expense is classified under general & administrative expense in the Consolidated Statement of Operations.
	The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices. Accounts receivable consisted of the following at June 30, 2013 and December 31, 2012:
			As of			As of
			June 30, 2013			December 31, 2012
	Accounts receivable		$	10,492,646		$	4,416,193
	Less: allowance for discounts			-1,004,000			-1,088,720
	Less: allowance for doubtful accounts			-253,552			-25,129
	Accounts receivable – net		$	9,235,094		$	3,302,344
	At June 30, 2013 and December 31, 2012, the Company had the following concentrations of accounts receivable with significant customers:
	Customer		As of June 30, 2013				As of December 31, 2012
	A			14	%			19	%
	B			8	%			6	%
	C			7	%			0	%
	Inventory
	Inventory is valued at the lower of cost or market value. Product-related inventories are primarily maintained using the average cost method.
	Prepaid Giveaways
	Prepaid giveaways represent non-inventory sample items, which are given away to aid in promotion of the brand.
	Prepaid Sponsorship Fees
	Prepaid sponsorship fees represents fees paid in connection with future advertising to be received.
	Property and Equipment
	Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in operating income in the statements of operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment.
	Website Development Costs
	Costs incurred in the planning stage of a website are expensed, while costs incurred in the development stage are capitalized and amortized over the estimated useful life of the asset.
	Long-Lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances, such as service discontinuance or technological obsolescence, indicate that the carrying amount of the long-lived asset may not be recoverable. When such events occur, the Company compares the carrying amount of the asset to the undiscounted expected future cash flows related to the asset. If the comparison indicates that impairment is present, the amount of the impairment is calculated as the difference between the excess of the carrying amount over the fair value of the asset. If a readily determinable market price does not exist, fair value is estimated using discounted expected cash flows attributable to the asset. During the six months ended June 30, 2013 and 2012, the Company recorded no impairment expense.
	Fair Value of Financial Instruments
	The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements contains a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchical levels of inputs to measure fair value:
		⋅	Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
		⋅	Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		⋅	Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.
	The following are the major categories of liabilities measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):
			As of June 30, 2013			As of December 31, 2012
	Derivative liabilities (Level 2)		$	2,369,032		$	-
	The Company’s financial instruments consisted primarily of accounts receivable, accounts payable and accrued liabilities, and debt. The Company’s debt approximates fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of June 30, 2013 and December 31, 2012, respectively, due to the short-term nature of these instruments.
	Revenue Recognition
	The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.
	Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all of our Canadian sales, which represent 3% of total sales, recognition occurs upon shipment.
	The Company has determined that advertising related credits that are granted to customers fall within the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives – Implementation Guidance and Illustrations). The guidance indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.
	The Company records sales allowances and discounts as a direct reduction of sales.
	Sales for the three and six months ended June 30, 2013 and 2012 were as follows:
			Three Months Ended June 30,						Six Months Ended June 30,
			2013			2012			2013		2012
	Sales		$	28,515,483		$	18,869,103		$	53,439,519	$	38,171,872
	Discounts			-3,035,424			-3,439,763			-5,398,293		-6,181,852
	Sales - Net		$	25,480,059		$	15,429,340		$	48,041,226	$	31,990,020
	The Company has an informal seven day right of return for products. There were nominal returns for the three and six months ended June 30, 2013 and 2012.
	For the three and six months ended June 30, 2013 and 2012, the Company had the following concentrations of revenues with significant customers:
			Three Months Ended June 30,
	Customer		2013				2012
	A			25	%			33	%
B			11	%			8	%
C			6	%			1	%
		Six Months Ended June 30,
Customer		2013				2012
A			29	%			40	%
B			11	%			11	%
C			6	%			17	%
Licensing Income and Royalty Revenue
On May 5, 2011, the Company granted an exclusive indefinite license to market, manufacture, design and sell the Company’s existing apparel line. The licensee paid an initial fee of $250,000 in June 2011, and will pay the Company a 10% net royalty based on its net income at the end of each fiscal year. To date, no royalty revenue has been earned by the Company.
Cost of Sales
Cost of sales represents costs directly related to the production, manufacturing and freight of the Company’s products.
Shipping and Handling
Until March 1, 2013 MusclePharm used a manufacturer from Tennessee to ship directly to our customers, and after that date MusclePharm took control of the shipping and began shipping product to our customers from a previously leased 152,000 square foot distribution center in Franklin, Tennessee in close proximity of our manufacturer. Our products are transported from our manufacturer to the MusclePharm distribution center, but title does not pass from the manufacturer until loaded on the truck for shipment. Through June 30, 2013, MusclePharm does not take title to our products (see Note 11). The facility in Franklin, Tennessee is operated with the Company’s equipment and employees. This transition away from having our Tennessee manufacturer ship product for us is an effort to reduce our costs and improve gross margins.
The Company also uses a manufacturer in New York for the manufacture of one of the Company’s products. These orders are typically large and heavy and are drop shipped directly to our customers at the time of order.
Costs associated to the shipments are recorded in cost of sales. For Canadian sales, the product is shipped from our Canadian warehouse to our customers. Costs associated with the shipments are recorded as shipping.
Advertising
The Company expenses advertising costs when incurred.
Advertising expense for the three and six months ended June 30, 2013 and 2012 were as follows:
		Three Months Ended June 30,						Six Months Ended June 30,
		2013			2012			2013		2012
Advertising		$	3,275,200		$	2,044,005		$	5,592,577	$	3,976,840
Beneficial Conversion Feature
For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount.
When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt.
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities consists of the Company’s trade payables as well as amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.
Debt
The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 4 for further disclosure of debt liabilities.
Derivative Liabilities
Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.
Once derivative liabilities are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid in capital.
Deferred Equity Costs
The Company may pay costs related to the underwriting and offering of equity securities. These costs are treated as a reduction to equity capital raised and recorded in equity when the share issuances are recorded. Until the shares are recorded or until offering is aborted, these costs will be held on the balance sheet as a deferred asset.
Debt Issue Costs and Debt Discount
The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of debt. These costs are amortized over the life of the debt to interest expense. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.
Original Issue Discount
For certain convertible debt issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded to debt discount and additional paid-in capital at an amount not to exceed gross proceeds raised, reducing the face amount of the debt, and is amortized to interest expense over the life of the debt.
Share-Based Payments
Generally, all forms of share-based payments, including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.
Earnings (loss) Per Share
Net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.
The Company uses an “if converted” method to determine whether there is a dilutive effect of outstanding option and warrant contracts. For the three months ended June 30, 2012, all of the Company’s convertible debt options and 625,028 warrants had exercise prices below of the Company’s period end market price of the common stock into which they convert. The adjusted dilutive net loss reflects the add back of approximately $349 of interest expense related to the convertible debt and the reduction of $9,449,050 of gains on derivative contracts for the three months ended June 30, 2012. For the three months ended June 30, 2013 and six months ended June 30, 2013 and 2012, and the three months ended June 30, 2012 the Company reflected net loss and a dilutive net loss, respectively, and the effect of considering any common stock equivalents would have been anti-dilutive for these periods. Therefore, separate computation of diluted earnings (loss) per share is not presented.
The Company has the following common stock equivalents for the six months ended June 30, 2013 and 2012, respectively:
		Six Months Ended June 30,
		2013			2012
Stock options (exercise price - $425/share)			670			1,903
Warrants (exercise price $4 – $1,275/share)			330,089			84,820
Convertible debt (exercise price $17/share)			-			2,471
Total common stock equivalents			330,759			89,194
In the above table, some of the outstanding instruments from 2013 and 2012 contain ratchet provisions that would cause variability in the exercise price at the balance sheet date. As a result, common stock equivalents could change at each reporting period.
Foreign Currency
MusclePharm began operations in Canada in April of 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are exchanged in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into United States Dollars, which is our reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the period and the assets and liabilities at the end of period rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and held in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.
Reclassification
The Company has reclassified certain prior period amounts to conform to the current period presentation. These reclassifications had no effect on the financial position, results of operations or cash flows for the periods presented.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 3: Property and Equipment
	Property and equipment consisted of the following at June 30, 2013 and December 31, 2012:
		As of June 30, 2013		As of December 31, 2012		Estimated Useful Life
	Furniture, fixtures and gym equipment	$	1,591,642	$	1,323,998	From 36 to 60 months
	Leasehold improvements		601,625		563,204	From 42 to 66 months
	Vehicles		100,584		100,584	5 years
	Displays		32,057		32,057	5 years
	Website		11,462		11,462	3 years
	Total		2,337,370		2,031,305
	Less: Accumulated depreciation and amortization		-1,008,323		-674,941
		$	1,329,047	$	1,356,364

Debt

Debt	6 Months Ended
	Jun. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 4: Debt
	At June 30, 2013 and December 31, 2012, debt consists of the following:
		As of June 30, 2013			As of December 31, 2012
	Auto loan - secured	$	9,729			15,380
	Unsecured debt		64,600			4,452,183
	Less: debt discount		-			-
	Unsecured debt - net		64,600			4,452,183
	Total debt		74,329			4,467,563
	Less: current portion		-74,329			-4,463,040
	Long term debt	$	-		$	4,523
	Debt in default of $64,600 at June 30, 2013 and December 31, 2012 is included as a component of short-term debt.
	Future annual principal payments for the above debt is as follows:
	Years Ending December 31,
	2013 (6 months)	$	70,840
	2014		3,489
	Total annual principal payments	$	74,329
	Convertible Debt – Secured - Derivative Liabilities
	During the year ended December 31, 2012, the Company issued convertible debt totaling $519,950. The convertible debt includes the following terms:
				Year Ended
				December 31, 2012
				Amount of
				Principal Raised
	Interest Rate				8% - 10%
	Default interest rate				0% - 20%
	Maturity				January 3, 2012 to October 11, 2014
	Conversion terms 1	62% of lowest trade price for the last 7 trading days			100,000
	Conversion terms 2	65% of the lowest trade price in the 30 trading days previous to the conversion			19,950
	Conversion terms 3	35% multiplied by the average of the lowest three (3) trading prices (as defined below) for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date.			400,000
				$	519,950
	The debt holders are entitled, at their option, to convert all or part of the principal and accrued interest into shares of the Company’s common stock at the conversion prices and terms discussed above. The Company classifies embedded conversion features in these notes as a derivative liability due to management’s assessment that the Company may not have sufficient authorized number of shares of common stock required to net-share settle or due to the existence of a ratchet due to an anti-dilution provision. See Note 5 regarding accounting for derivative liabilities.
	(A) Unsecured Debt
	Unsecured debt consisted of the following activity and terms:
	Balance - December 31, 2012	$	4,452,183
	Repayments		-4,387,583
	Balance – June 30, 2013	$	64,600
	(B) Vehicle Loan
	Vehicle loan account consisted of the following activity and terms:
					Interest Rate			Maturity
	Balance - December 31, 2012	$	15,380			6.99	%		26 payments of $1,008
	Repayments		-5,651
	Balance – June 30, 2013	$	9,729
	(C) Debt Issue Costs
	During the six months ended June 30, 2012, the Company paid debt issue costs totaling $106,950.
	For the year ended December 31, 2012, the Company issued 22,633 warrants as cost associated with a debt raise. The initial derivative liability value of $427,759 was recorded as debt issue costs and derivative liability.
	The following is a summary of the Company’s debt issue costs for the six months ended June 30, 2013 and year ended December 31, 2012 as follows:
		2013			2012
	Debt issue costs	$	335,433		$	851,923
	Accumulated amortization of debt issue costs		-335,433			-516,490
	Debt issue costs – net	$	-		$	335,433
	During the six months ended June 30, 2013 and 2012, the Company amortized $335,433 and $184,031, respectively in debt issue costs.

Derivative_Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Fair Value [Text Block]	'
	Note 5: Derivative Liabilities
	The Company identified conversion features embedded within consulting agreements and Series D Preferred Stock issued in 2013. The Company has determined that the features associated with the embedded conversion option should be accounted for at fair value as a derivative liability as the Company could not determine if a sufficient number of shares would be available to settle all transactions.
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2012	$	-
	Fair value at the commitment date for equity instruments		8,175,459
	Fair value at the commitment date for warrants issued		96,913
	Fair value mark to market adjustment for equity instruments		5,716,688
	Fair value mark to market adjustment for warrants		55,275
	Conversion instruments exercised		-11,675,303
	Derivative liability – June 30, 2013	$	2,369,032
	The Company recorded the day 1 value of derivative contracts associated with the Series D preferred stock issuance against gross proceeds raised, and expensed immediately the remaining value of the derivative as it exceeded the gross proceeds of the offering. The Company recorded a derivative expense of $96,913 and $2,486,451 for the six months ended June 30, 2013 and 2012, respectively.
	The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions:
		Commitment Date			Re-measurement Date
	Expected dividends		0	%		0	%
	Expected volatility		118% - 123	%		107	%
	Expected term:		1 year			17 months – 1 year
	Risk free interest rate		0.14% - 0.15%			0.15	%

Restricted_Stock_Units

Restricted Stock Units	6 Months Ended
	Jun. 30, 2013
Schedule Of Share Based Compensation Restricted Stock and Restricted Stock Units [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	Note 6: Restricted Stock Units
	In November 2012, the Company granted the Executive Vice President and Co-Chairman, Mr. John H. Bluher, 70,589 restricted stock units through a restricted stock unit agreement. Each restricted stock unit represents a contingent right to receive one share of the Company’s common stock upon vesting. The value of this award at the grant date was $245,400 and will be amortized over the vesting periods such that each tranche of restricted stock units will be fully amortized at the date of vesting.  The restricted stock units vest in one tranche of 23,529 on January 1, 2013 and two tranches of 23,530 shares on January 1, 2014 and December 1, 2014.  As of June 30, 2013, 23,529 restricted stock units have vested and the unamortized portion of this award is $123,036.
	In November 2012, the Company granted the Chief Financial Officer, Mr. L. Gary Davis, 58,824 restricted stock units through a restricted stock unit agreement. Each restricted stock unit represents a contingent right to receive one share of the Company’s common stock upon vesting. The value of this award at the grant date was $204,500 and will be amortized over the vesting periods such that each tranche of restricted stock units will be fully amortized at the date of vesting.  The restricted stock units vest in three tranches of 19,608 shares each on January 1, 2013 and 2014, and December 1, 2014.  As of June 30, 2013, 19,608 restricted stock units have vested and the unamortized portion of this award is $102,530.

Stockholders_Equity

Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

'

Stockholders' Equity Note Disclosure [Text Block]

'

Note 7: Stockholders’ Equity

The Company has four separate series of authorized preferred stock:

On November 26, 2012, the Company (i) effected a 1-for-850 reverse stock split of our common stock, including a proportionate reduction in the number of authorized shares of our common stock from 2.36 billion shares to 2.8 million shares of common stock, and (ii) amended our articles of incorporation to increase the number of authorized shares of common stock (post reverse stock split) from 2,941,177 to 100 million effective November 27, 2012.  All share and per share amounts in this document have been changed to give effect to the reverse stock split.

(A) Series A Convertible Preferred Stock

This class of stock has the following provisions:

⋅

Non-voting,

⋅

No rights to dividends,

⋅

No liquidation value, and

⋅

Convertible into 200 shares of common stock.

(B) Series B Preferred Stock (Related Parties)

In August 2011, the Company issued an aggregate of 51 shares of Series B Preferred Stock to two of its officers. The Company accounted for the share issuance at par value as there was no future economic value that could be associated with the issuance.

This class of stock has the following provisions:

·

Voting rights entitling the holders to an aggregate 51% voting control,

⋅

No rights to dividends,

⋅

Stated value of $0.001 per share,

⋅

Liquidation rights entitle the receipt of net assets on a pro-rata basis with the holders of our common stock; and

⋅

Non-convertible.

(C) Series C Convertible Preferred Stock

In October 2011, the Company issued 190 shares of Series C Convertible Preferred Stock, having a fair value of $190,000. Of the total shares issued, 100 shares were issued for $100,000 ($1,000 /share). The remaining 90 shares were issued for services rendered having a fair value of $90,000 ($1,000 /share), based upon the stated value per share. In March 2012, all 190 shares were converted into 22,353 shares of the Company’s common stock at a conversion price of $0.0085 per share and a loss of $614,984.

This class of stock has the following provisions:

⋅

Stated Value - $1,000 per share,

⋅

Non-voting,

⋅

Liquidation rights entitle an amount equal to the stated value, plus any accrued and unpaid dividends,

⋅

As long as any Series C, Convertible Preferred Stock is outstanding, the Company is prohibited from executing various corporate actions without the majority consent of the holders of Series C, Convertible Preferred Stockholders authorization; and

⋅

Convertible at the higher of (a) $0.01 or (b) such price that is a 50% discount to market using the average of the low two closing bid prices, five days preceding conversion.

Due to the existence of an option to convert at a variable amount, the Company treated this series of preferred stock as a derivative liability due to the potential for settlement in a variable quantity of shares. Additionally, the Company computed the fair value of the derivative liability at the commitment date and re-measurement date, which was $293 and $175, respectively, using the Black-Scholes assumptions below. This transaction is analogous to a dividend with a direct charge to retained earnings.

(D) Series D Convertible Preferred Stock

In January 2013 the board of directors authorized 1,600,000 shares of Series D convertible preferred stock. Between January 16, 2013 and February 4, 2013, the Company entered into separate subscription agreements with certain investors in connection with the offering, pursuant to which the Company sold an aggregate of 1,500,000 shares of Preferred Stock for aggregate gross proceeds of approximately $12 million. Pursuant to the Certificate of Designation of the Series D Convertible Preferred Stock filed with the Nevada Secretary of State on January 11, 2013 (the “Certificate of Designation”), each share of Preferred Stock is convertible into two shares of common stock, subject to adjustment as set forth in the Certificate of Designation.

The shares of Series D have the following provisions:

⋅

Voting rights based on number of common shares of conversion option;

⋅

Initially no rights to dividends;

⋅

Liquidation rights entitle an amount equal to the stated value, plus any accrued and unpaid dividends,

⋅

Convertible into 2 shares of common stock, subject to adjustment.

(E) Common Stock

During the six months ended June 30, 2013, the Company issued the following common stock:

Transaction Type

Quantity

Valuation

Range of Value

(#)

($)

per Share

($)

Conversion of Series D preferred stock to common stock

2,710,000

11,675,481

2.80 – 7.54

Cash and warrants

953,236

8,059,330

8.26 – 9.32

Executive/Board of Director compensation

62,289

264,879

3.48 – 6.00

Stock issued for services and to settle liabilities

1,262,830

9,894,844

4.02 – 12.99

Total

4,988,355

29,894,534

2.80 – 12.99

The fair value of all stock issuances above is based upon either the quoted closing trading price on the date of issuance, the value of derivative instrument at the date of conversion, contract value where the fair value was stated by the contract, or net proceeds from capital raised after giving effect to the cost of capital raised.

(F) Stock Options

The Company applied fair value accounting for all shares based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used when the options were issued in the year ended December 31, 2010 are as follows:

Exercise price

$

425

Expected dividends

0

%

Expected volatility

74.8

%

Risk fee interest rate

1.4

%

Expected life of option

5 years

Expected forfeiture

0

%

The following is a summary of the Company’s stock option activity:

Options

Weighted Average

Weighted Average

Aggregate Intrinsic

Exercise Price

Remaining

Value

Contractual Life

Balance – December 31, 2012

1,847

$

425

2.25 years

-

Granted

-

Exercised

-

Forfeited/Cancelled

-1,177

$

425

Balance – June 30, 2013 – outstanding

670

$

425

1.75 years

-

Balance – June 30, 2013 – exercisable

670

$

425

1.75 years

-

Outstanding options held by related parties – 2013

-

Exercisable options held by related parties – 2013

-

(G) Stock Warrants

All warrants issued during the six months ended June 30, 2013 were accounted for as derivative liabilities. See Note 5.

During the six months ended June 30, 2013, the Company entered into convertible equity agreements. As part of these agreements, the Company issued warrants to convert 1,500,000 shares of Series D preferred stock into 3,000,000 shares of common stock.

A summary of warrant activity for the Company for the six months ended June 30, 2013 is as follows:

Number of Warrants

Weighted Average Exercise Price

Outstanding – December 31, 2012

89

$

1,275

Granted

3,040,000

4.09

Exercised

-2,710,000

4

Balance as June 30, 2013

330,089

$

5.13

Warrants Outstanding

Warrants Exercisable

Range of

Number

Weighted Average

Weighted Average

Number

Weighted

Intrinsic Value

Exercise Prices

Outstanding

Remaining

Exercise Price

Exercisable

Average

Contractual Life (in

Exercise Price

years)

$4 - $1,275

330,089

0.95

$

5.13

330,089

$

5.13

1,340,000

(H) Treasury Stock

During the six months ended June 30, 2013, the Company repurchased 18,825 shares of its common stock for the total sum of $260,000 as part of a settlement. Of this amount, 103,537 or $5.50 per share was considered repurchase of securities and $156,463 was recorded as a loss on settlement. The Company records the value of its common stock held in treasury at cost. The Company has not cancelled or retired these shares, and they remain available for reissuance. The Company has a stock repurchase plan in place but has suspended it indefinitely.

(I) Consulting Agreement

On July 19, 2012, we entered into a consulting agreement (the “Original GRQ Consulting Agreement”) with GRQ Consultants, Inc. (“GRQ”, and together with Melechdavid, collectively, the “Consultants”). The Original GRQ Consulting Agreement provides that the Company will issue to GRQ shares of common stock in an amount equal to 4.2% of the Company’s outstanding common stock on a fully diluted (as-converted) basis. Further, until July 12, 2014, the Company is required to ensure that GRQ shall maintain its 4.2% fully diluted equity position. The term of the Original GRQ Consulting Agreement is 12 months.

On April 2, 2013, the Company entered into a first amendment to the Original Melechdavid Consulting Agreement with Melechdavid, effective as of March 28, 2013 (the “Melechdavid Amended Agreement”). Pursuant to the Melechdavid Amended Agreement, Melechdavid agreed to cap the shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) that it is entitled to receive under the Original Melechdavid Consulting Agreement to no more than 570,000 shares of Common Stock of the Company, after giving effect to the 1-for-850 reverse stock split of the Common Stock effected by the Company on November 26, 2012. In connection with the execution and delivery of the Melechdavid Amended Agreement, the Company issued Melechdavid an aggregate of 341,247 shares of Common Stock on March 29, 2013 and 228,753 shares of Common Stock on April 5, 2013 as full satisfaction of the Company’s obligations under the Original Melechdavid Consulting Agreement.

On April 2, 2013, the Company entered into a first amendment to the Original GRQ Consulting Agreement with GRQ, effective as of March 28, 2013 (the “GRQ Amended Agreement”). Pursuant to the GRQ Amended Agreement, GRQ agreed to cap the shares of the Company’s Common Stock that it is entitled to receive under the Original GRQ Consulting Agreement to no more than 420,000 shares of Common Stock of the Company, after giving effect to the 1-for-850 reverse stock split of the Common Stock effected by the Company on November 26, 2012. In connection with the execution and delivery of the GRQ Amended Agreement, the Company issued GRQ an aggregate of 305,889 shares of Common Stock on March 29, 2013 and 78,753 shares of Common Stock on April 5, 2013 as full satisfaction of the Company’s obligations under the Original GRQ Consulting Agreement. The Company had previously issued GRQ 35,359 shares of Common Stock pursuant to the Original GRQ Consulting Agreement.

During the three and six months period ending June 30, 2013, the Company recognized expense related to the GRQ and Melechdavid agreements of $3,037,636 and $6,591,816, respectively. These expenses are classified under General and Administrative Expenses in the Consolidated Statement of Operations. The Company’s obligations under the GRQ and Melechdavid agreements were completely satisfied as of July 12, 2013 and the agreements have not been renewed or extended.

Committments_Contingencies_and

Committments, Contingencies and Other Matters	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 8: Commitments, Contingencies and Other Matters
	(A) Operating Lease
	The Company has various non-cancelable leases with terms expiring through 2017.
	Future minimum annual lease payments for the above leases are approximately as follows:
	Years Ending December 31,
	2013 (6 months)		$	246,608
	2014			556,868
	2015			391,069
	2016			79,860
	2017			19,965
	Total minimum lease payments		$	1,294,370
	Rent expense for the six months ended June 30, 2013 and 2012, was $298,887 and $117,247, respectively.
	(B) Legal Matters
	From time to time, the Company is or may become involved in various legal proceedings that arise in the ordinary course of business or otherwise. Legal proceedings are subject to inherent uncertainties as to timing, outcomes, costs, expenses and time expenditures by the Company’s management and others on behalf of the Company. Although there can be no assurance, based on information currently available the Company’s management believes that the outcome of legal proceedings that are pending or threatened against the Company will not have a material effect on the Company’s financial condition. However, the outcome of any of these matters is neither probable nor reasonably estimable.
	As of June 30, 2013, the Company was a party defendant in the following legal proceedings, each of which the Company: (a) believes is without merit; and (b) intends to defend vigorously:
		⋅	The Tawnsaura Group, LLC v MusclePharm Corporation, Case No: 8:12-cv-01476-JVS-RNB in the United States District Court for the Central District of California.   Date instituted: September 12, 2012. Plaintiff alleges patent infringement for MusclePharm's use of Citrulline Malate in its products.  To date, Plaintiff has filed against over 70 different manufacturers of dietary supplements and sports nutrition products. MusclePharm is part of a joint defense group and believes this case is without merit due to the existence of prior art.
		⋅	William Bossung and Bishop Equity Partners LLC v. MusclePharm Corporation, Clark County, Nevada District Court. Date instituted: January 17, 2012. Plaintiff alleges that additional monetary payments are due in respect of a settlement for outstanding warrants.
		⋅	Nageen Dehesh v MusclePharm Corporation, Case No: SC120793 in the Superior Court of the State of California, County of Los Angeles West District.   Date instituted:  May 30, 2012.  Plaintiff alleges she is owed payment for introducing MusclePharm to investors and/or raising capital. Plaintiff is not a licensed broker dealer and there was no agreement between the parties.
	As of June 30, 2013, the Company was a party plaintiff in the following legal matters:
		⋅	MusclePharm Corporation v. Swole Sports Nutrition, LLC, United States District Court for the Southern District of Florida. Date instituted: March 15, 2012. The Company filed this action for trademark infringement against after the Defendant started marketing and selling a dietary supplement named “Turbo Shred”. The Company has sold “Shred Matrix” since April 2, 2008, and the mark “MusclePharm Shred Matrix” was granted registration by the USPTO on September 21, 2010. The parties have reached a coexistence and settlement agreement whereby the case would be dismissed.  The court dismissed the case on July 15, 2013.
	(C) Payroll Taxes
	As of June, 2013, accounts payable and accrued expenses included $87,339 pertaining to accrued payroll taxes. The taxes represent employee withholdings that have yet to be remitted to the taxing agencies.
	(D) Product Liability
	As a manufacturer of nutritional supplements and other consumer products that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any material claims to date, it is possible that current and future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains product liability insurance with a deductible/retention of $10,000 per claim with an aggregate cap on retained loss of $5,000,000. At June 30, 2013 the Company had not recorded any accruals for product liability claims.
	(E) Other Liabilities and Regulatory Matters
	Subsequent to December 31, 2012, the Company determined that it may have potential liabilities related to the filing of certain informational returns required by governmental authorities.  Management has developed a plan to address these matters and does not currently expect a significant adverse impact on its financial position or results of operations.

Defined_Contribution_Plan

Defined Contribution Plan	6 Months Ended
	Jun. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 9: Defined Contribution Plan
	The Company established a 401(k) Plan (the “401(k) Plan”) for eligible employees of the Company. Generally, all employees of the Company who are at least twenty-one years of age and who have completed one year of entry service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make voluntary salary deferral contributions, on a pretax basis, of up to $17,000 for 2012 (subject to make-up contributions) in the form of voluntary payroll deductions. The Company may make discretionary contributions. During the six months ended June 30, 2013 and 2012 the Company’s matching contribution was $28,530 and $18,251, respectively.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 10: Related Party Transactions
	The Chief Executive Officer of one of our major customers is the brother of our Chief Marketing Officer.  Our Chief Financial Officer also indirectly owns 1.75% of the equity interest in such customer. We do not offer preferential pricing of our products to this customer based on these relationships.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 11: Subsequent Events
		(A)	Restricted Stock Grant
	On June 25, 2013, our board of directors (“Board”) approved restricted stock grants (the “Restricted Stock”) to certain key employees, including named executive officers and directors, conditioned upon the execution and delivery of certain restricted stock agreement between the Company and such employees, officers and directors (the “Restricted Stock Agreements”). The Restricted Stock Agreements were executed and delivered by the parties on July 5, 2013.  The Board approved Restricted Stock grants of the Company’s common stock in the aggregate amount of 1,550,000 shares including shares of the Company’s restricted stock to the following named executive officers and directors in the following amounts:
	Name		Title	Number of Shares of Restricted Stock
	Brad J. Pyatt		Co-Chairman, CEO and President		350,000
	L. Gary Davis		Chief Financial Officer		200,000
	John H. Bluher		Co-Chairman and Executive Vice President		150,000
	Richard Estalella		Chief Operating Officer		100,000
	Jeremy R. DeLuca		Executive Vice President – Chief Marketing Officer		225,000
	Cory J. Gregory		Executive Vice President		150,000
	Michael Doron		Director		25,000
	James Greenwell		Director		25,000
	Donald W. Prosser		Director		25,000
	Pursuant to the Restricted Stock agreements, seventeen percent (17%) of each individual grant shall vest on December 31, 2013, and the remaining 83% shall vest on December 31, 2015. The grants for all will vest immediately upon (i) a change of control, and are subject to, such executive and/or employees continued employment, and in the case of any director, such director’s continued service on the Board, and (ii) an employee, who has an entered into an employment agreement with the Company, serving the duration of the term of such employment agreement in accordance with its terms. The total value on the date of the grant was $17,065,500, and will be amortized over the vesting periods as described above with the exception of certain executives under employment agreements that terminate prior to December 31, 2015. Those executives’ grants will be amortized over the remaining term of their employment agreements.
		(B)	Inventory
	On July 1, 2013, the Company substantially terminated a Distribution Agreement dated November 17, 2010 with one of our key product manufacturers in which the manufacturer received and fulfilled customer sales orders for a majority of our products as more fully discussed in the “Shipping and Handling” section of Note 2 above . In connection with the termination of the agreement, we purchased an aggregate $4,664,421 of product inventory, and the Company took back control of customer order fulfillment through our Franklin, Tennessee warehouse.
		(C)	Endorsement Agreements
	On July 26, 2013, the Company entered into an Endorsement Licensing and Co-Branding Agreement by and among, the Company, Arnold Schwarzenegger, Marine MP, LLC, and Fitness Publications, Inc. Under the terms of the Agreement, Mr. Arnold Schwarzenegger will endorse the Company’s products and a special Arnold Schwarzenegger product line of between 4 and 8 products will be marketed under Mr. Schwarzenegger’s name and likeness. In connection with this agreement, the Company issued Marine MP, LLC 780,000 restricted shares of common stock.
	(D)  Board of Directors and Corporate Officer Changes
	On August 6, 2013, our board of directors appointed both Richard Estalella and Daniel J. McClory to serve on the Company’s Board of Directors. The Board of Directors has determined that Mr. McClory is an independent director pursuant to the rules of the NASDAQ stock market. Mr. Estalella joined the Company in April of 2013 and has served since that time as Chief Operating Officer.
	There is no family relationship between either of Mr. Estalella or Mr. McClory and any of our other officers and directors. There are no understandings or arrangements between either of Mr. Estalella or Mr. McClory and any other person pursuant to which either was selected as an officer.
	Except for the aforementioned arrangements, there has not been any transaction or currently proposed transaction, in which the Company was or is to be a participant and the amount involved exceeds $120,000, and in which either of Mr. Estalella or Mr. McClory had or will have a direct or indirect material interest since the beginning of the Company’s last fiscal year.
	Additionally, on August 6, 2013, Jeremy R. DeLuca and the Company agreed that Mr. DeLuca’s title with the Company would be changed from that of Executive Vice President and Chief Marketing Officer to President of Sales and Marketing. The Board of Directors voted to accept this new designation. Accordingly, Mr. DeLuca will no longer be a named executive officer, including for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The change in Mr. DeLuca’s title was not as a result of any disagreements between him and the Company including with respect to the Company’s operations, policies or practices.
		(E)	Private Placement of Stock
	On August 9, 2013 the Company closed a $2.5 million common stock offering. MusclePharm entered into subscription agreements with accredited investors whereby it sold 238,096 restricted shares of its common stock at $10.50 per share. At the time of filing this report on Form 10-Q, these shares had not been issued but will be issued in the very near future.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

'

Consolidation, Policy [Policy Text Block]

'

Principles of Consolidation

The consolidated financial statements include the accounts of MusclePharm Corporation and its wholly-owned subsidiary MusclePharm Canada Enterprises Corp (“MusclePharm Canada”). MusclePharm Canada began operations in April of 2012. All intercompany accounts and transactions between MusclePharm Corporation and MusclePharm Canada have been eliminated upon consolidation.

Use of Estimates, Policy [Policy Text Block]

'

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

Risks and Uncertainties [Policy Text Block]

'

Risks and Uncertainties

The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, industry adverse publicity and other risks, including the potential risk of business failure.

Cash and Cash Equivalents, Policy [Policy Text Block]

'

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of three months or less and money market accounts to be cash equivalents. At June 30, 2013 and December 31, 2012, respectively, the Company had no cash equivalents.

Accounts Receivable and Allowance For Doubtful Accounts [Policy Text Block]

'

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable represents trade obligations from customers that are subject to normal trade collection terms. Prior to July 1, the accounts receivable were sent directly to the Company’s third party manufacturer and netted with any outstanding liabilities to the manufacturer (see Note 11). Liabilities to the manufacturer totaled $4,213,394 at June 30, 2013 and are included in accounts payable and accrued liabilities. The Company periodically evaluates the collectability of its accounts receivable and considers the need to establish an allowance for doubtful accounts based upon historical collection experience and specific customer information. Accordingly, the actual amounts could vary from the recorded allowances. There is also a review of customer discounts at the period end and an accrual made for discounts earned but not yet received by quarter end.

Management reserves for bad debt expense based on the aging of accounts receivable. Bad debt expense is classified under general & administrative expense in the Consolidated Statement of Operations.

The Company does not charge interest on past due receivables. Receivables are determined to be past due based on the payment terms of the original invoices. Accounts receivable consisted of the following at June 30, 2013 and December 31, 2012:

As of

As of

June 30, 2013

December 31, 2012

Accounts receivable

$

10,492,646

$

4,416,193

Less: allowance for discounts

-1,004,000

-1,088,720

Less: allowance for doubtful accounts

-253,552

-25,129

Accounts receivable – net

$

9,235,094

$

3,302,344

At June 30, 2013 and December 31, 2012, the Company had the following concentrations of accounts receivable with significant customers:

Customer

As of June 30, 2013

As of December 31, 2012

A

14

%

19

%

B

8

%

6

%

C

7

%

0

%

Inventory, Policy [Policy Text Block]

'

Inventory

Inventory is valued at the lower of cost or market value. Product-related inventories are primarily maintained using the average cost method.

Prepaid Giveaways [Policy Text Block]

'

Prepaid Giveaways

Prepaid giveaways represent non-inventory sample items, which are given away to aid in promotion of the brand.

Prepaid Sponsorship Fees [Policy Text Block]

'

Prepaid Sponsorship Fees

Prepaid sponsorship fees represents fees paid in connection with future advertising to be received.

Property, Plant and Equipment, Policy [Policy Text Block]

'

Property and Equipment

Property and equipment are stated at cost and depreciated to their estimated residual value over their estimated useful lives. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are relieved from the accounts and the resulting gains or losses are included in operating income in the statements of operations. Repairs and maintenance costs are expensed as incurred. Depreciation is provided using the straight-line method for all property and equipment.

Website Development Cost [Policy Text Block]

'

Website Development Costs

Costs incurred in the planning stage of a website are expensed, while costs incurred in the development stage are capitalized and amortized over the estimated useful life of the asset.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

'

Long-Lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances, such as service discontinuance or technological obsolescence, indicate that the carrying amount of the long-lived asset may not be recoverable. When such events occur, the Company compares the carrying amount of the asset to the undiscounted expected future cash flows related to the asset. If the comparison indicates that impairment is present, the amount of the impairment is calculated as the difference between the excess of the carrying amount over the fair value of the asset. If a readily determinable market price does not exist, fair value is estimated using discounted expected cash flows attributable to the asset. During the six months ended June 30, 2013 and 2012, the Company recorded no impairment expense.

Fair Value of Financial Instruments, Policy [Policy Text Block]

'

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements contains a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

⋅

Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

⋅

Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

⋅

Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The following are the major categories of liabilities measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

As of June 30, 2013

As of December 31, 2012

Derivative liabilities (Level 2)

$

2,369,032

$

-

The Company’s financial instruments consisted primarily of accounts receivable, accounts payable and accrued liabilities, and debt. The Company’s debt approximates fair value based upon current borrowing rates available to the Company for debt with similar maturities. The carrying amounts of the Company’s financial instruments generally approximated their fair values as of June 30, 2013 and December 31, 2012, respectively, due to the short-term nature of these instruments.

Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]

'

Revenue Recognition

The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) product has been shipped or delivered, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.

Depending on individual customer agreements, sales are recognized either upon shipment of products to customers or upon delivery. For all of our Canadian sales, which represent 3% of total sales, recognition occurs upon shipment.

The Company has determined that advertising related credits that are granted to customers fall within the guidance of ASC No. 605-50-55 (“Revenue Recognition” – Customer Payments and Incentives – Implementation Guidance and Illustrations). The guidance indicates that, absent evidence of benefit to the vendor, appropriate treatment requires netting these types of payments against revenues and not expensing as advertising expense.

The Company records sales allowances and discounts as a direct reduction of sales.

Sales for the three and six months ended June 30, 2013 and 2012 were as follows:

Three Months Ended June 30,

Six Months Ended June 30,

2013

2012

2013

2012

Sales

$

28,515,483

$

18,869,103

$

53,439,519

$

38,171,872

Discounts

-3,035,424

-3,439,763

-5,398,293

-6,181,852

Sales - Net

$

25,480,059

$

15,429,340

$

48,041,226

$

31,990,020

The Company has an informal seven day right of return for products. There were nominal returns for the three and six months ended June 30, 2013 and 2012.

For the three and six months ended June 30, 2013 and 2012, the Company had the following concentrations of revenues with significant customers:

Three Months Ended June 30,

Customer

2013

2012

A

25

%

33

%

B

11

%

8

%

C

6

%

1

%

Six Months Ended June 30,

Customer

2013

2012

A

29

%

40

%

B

11

%

11

%

C

6

%

17

%

Licensing Income and Royalty Revenue [Policy Text Block]

'

Licensing Income and Royalty Revenue

On May 5, 2011, the Company granted an exclusive indefinite license to market, manufacture, design and sell the Company’s existing apparel line. The licensee paid an initial fee of $250,000 in June 2011, and will pay the Company a 10% net royalty based on its net income at the end of each fiscal year. To date, no royalty revenue has been earned by the Company.

Cost of Sales, Policy [Policy Text Block]

'

Cost of Sales

Cost of sales represents costs directly related to the production, manufacturing and freight of the Company’s products.

Shipping and Handling Cost, Policy [Policy Text Block]

'

Shipping and Handling

Until March 1, 2013 MusclePharm used a manufacturer from Tennessee to ship directly to our customers, and after that date MusclePharm took control of the shipping and began shipping product to our customers from a previously leased 152,000 square foot distribution center in Franklin, Tennessee in close proximity of our manufacturer. Our products are transported from our manufacturer to the MusclePharm distribution center, but title does not pass from the manufacturer until loaded on the truck for shipment. Through June 30, 2013, MusclePharm does not take title to our products (see Note 11). The facility in Franklin, Tennessee is operated with the Company’s equipment and employees. This transition away from having our Tennessee manufacturer ship product for us is an effort to reduce our costs and improve gross margins.

The Company also uses a manufacturer in New York for the manufacture of one of the Company’s products. These orders are typically large and heavy and are drop shipped directly to our customers at the time of order.

Costs associated to the shipments are recorded in cost of sales. For Canadian sales, the product is shipped from our Canadian warehouse to our customers. Costs associated with the shipments are recorded as shipping.

Advertising Costs, Policy [Policy Text Block]

'

Advertising

The Company expenses advertising costs when incurred.

Advertising expense for the three and six months ended June 30, 2013 and 2012 were as follows:

Three Months Ended June 30,

Six Months Ended June 30,

2013

2012

2013

2012

Advertising

$

3,275,200

$

2,044,005

$

5,592,577

$

3,976,840

Beneficial Conversion Feature [Policy Text Block]

'

Beneficial Conversion Feature

For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount.

When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument. The discount is amortized to interest expense over the life of the debt.

Accounts Payable and Accrued Liabilities [Policy Text Block]

'

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities consists of the Company’s trade payables as well as amounts estimated by management for future liability payments that relate to the current accounting period. Management reviews these estimates periodically to determine their reasonableness and fair presentation.

Debt, Policy [Policy Text Block]

'

Debt

The Company defines short term debt as any debt payment due less than one year from the date of the financial statements. Long term debt is defined as any debt payment due more than one year from the date of the financial statements. Refer to Note 4 for further disclosure of debt liabilities.

Derivatives, Policy [Policy Text Block]

'

Derivative Liabilities

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in equity instruments and warrants granted, and measurement of their fair value. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible equity instruments, management determines if the convertible equity instrument is conventional convertible equity and further if the beneficial conversion feature requires separate measurement.

Once derivative liabilities are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model. Once a derivative liability ceases to exist any remaining fair value is reclassified to additional paid in capital.

Deferred Equity Costs Policy [Policy Text Block]

'

Deferred Equity Costs

The Company may pay costs related to the underwriting and offering of equity securities. These costs are treated as a reduction to equity capital raised and recorded in equity when the share issuances are recorded. Until the shares are recorded or until offering is aborted, these costs will be held on the balance sheet as a deferred asset.

Debt Issue Costs and Debt Discount [Policy Text Block]

'

Debt Issue Costs and Debt Discount

The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of debt. These costs are amortized over the life of the debt to interest expense. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.

Original Issue Discount [Policy Text Block]

'

Original Issue Discount

For certain convertible debt issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded to debt discount and additional paid-in capital at an amount not to exceed gross proceeds raised, reducing the face amount of the debt, and is amortized to interest expense over the life of the debt.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

'

Share-Based Payments

Generally, all forms of share-based payments, including stock option grants, warrants and restricted stock grants and stock appreciation rights are measured at their fair value on the awards’ grant date, based on estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non- employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.

Earnings Per Share, Policy [Policy Text Block]

'

Earnings (loss) Per Share

Net earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period.

The Company uses an “if converted” method to determine whether there is a dilutive effect of outstanding option and warrant contracts. For the three months ended June 30, 2012, all of the Company’s convertible debt options and 625,028 warrants had exercise prices below of the Company’s period end market price of the common stock into which they convert. The adjusted dilutive net loss reflects the add back of approximately $349 of interest expense related to the convertible debt and the reduction of $9,449,050 of gains on derivative contracts for the three months ended June 30, 2012. For the three months ended June 30, 2013 and six months ended June 30, 2013 and 2012, and the three months ended June 30, 2012 the Company reflected net loss and a dilutive net loss, respectively, and the effect of considering any common stock equivalents would have been anti-dilutive for these periods. Therefore, separate computation of diluted earnings (loss) per share is not presented.

The Company has the following common stock equivalents for the six months ended June 30, 2013 and 2012, respectively:

Six Months Ended June 30,

2013

2012

Stock options (exercise price - $425/share)

670

1,903

Warrants (exercise price $4 – $1,275/share)

330,089

84,820

Convertible debt (exercise price $17/share)

-

2,471

Total common stock equivalents

330,759

89,194

In the above table, some of the outstanding instruments from 2013 and 2012 contain ratchet provisions that would cause variability in the exercise price at the balance sheet date. As a result, common stock equivalents could change at each reporting period.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

'

Foreign Currency

MusclePharm began operations in Canada in April of 2012. The Canadian Dollar was determined to be the functional currency as the majority of the transactions related to the day to day operations of the business are exchanged in Canadian Dollars. At the end of the period, the financial results of the Canadian operation are translated into United States Dollars, which is our reporting currency, and added to the U.S. operations for consolidated company financial results. The revenue and expense items are translated using the average rate for the period and the assets and liabilities at the end of period rate. Transactions that have completed the accounting cycle and resulted in a gain or loss related to translation are recorded in realized gain or loss due to foreign currency translation under other income expense on the income statement. Transactions that have not completed their accounting cycle but appear to have gain or loss due to the translation process are recorded as unrealized gain or loss due to translation and held in the equity section on the balance sheet until such date the accounting cycle of the transaction is complete and the actual realized gain or loss is recognized.

Reclassification, Policy [Policy Text Block]

'

Reclassification

The Company has reclassified certain prior period amounts to conform to the current period presentation. These reclassifications had no effect on the financial position, results of operations or cash flows for the periods presented.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]	'
Schedule Of Accounts Receivable [Table Text Block]	'
	Accounts receivable consisted of the following at June 30, 2013 and December 31, 2012:
		As of			As of
		June 30, 2013			December 31, 2012
	Accounts receivable	$	10,492,646		$	4,416,193
	Less: allowance for discounts		-1,004,000			-1,088,720
	Less: allowance for doubtful accounts		-253,552			-25,129
	Accounts receivable – net	$	9,235,094		$	3,302,344
Concentration Percentage Of Accounts Receivable With Customer [Table Text Block]	'
	At June 30, 2013 and December 31, 2012, the Company had the following concentrations of accounts receivable with significant customers:
	Customer	As of June 30, 2013				As of December 31, 2012
	A		14	%			19	%
	B		8	%			6	%
	C		7	%			0	%
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
	The following are the major categories of liabilities measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):
		As of June 30, 2013			As of December 31, 2012
	Derivative liabilities (Level 2)	$	2,369,032		$	-
Schedule Of Sales [Table Text Block]	'
	Sales for the three and six months ended June 30, 2013 and 2012 were as follows:
		Three Months Ended June 30,						Six Months Ended June 30,
		2013			2012			2013		2012
	Sales	$	28,515,483		$	18,869,103		$	53,439,519	$	38,171,872
	Discounts		-3,035,424			-3,439,763			-5,398,293		-6,181,852
	Sales - Net	$	25,480,059		$	15,429,340		$	48,041,226	$	31,990,020
Schedule Of Concentrations Of Revenues With Customers [Table Text Block]	'
	For the three and six months ended June 30, 2013 and 2012, the Company had the following concentrations of revenues with significant customers:
		Three Months Ended June 30,
	Customer	2013				2012
	A		25	%			33	%
	B		11	%			8	%
	C		6	%			1	%
		Six Months Ended June 30,
	Customer	2013				2012
	A		29	%			40	%
	B		11	%			11	%
	C		6	%			17	%
Schedule Of Advertising Expense [Table Text Block]	'
	Advertising expense for the three and six months ended June 30, 2013 and 2012 were as follows:
		Three Months Ended June 30,						Six Months Ended June 30,
		2013			2012			2013		2012
	Advertising	$	3,275,200		$	2,044,005		$	5,592,577	$	3,976,840
Schedule Of Common Stock Equivalents [Table Text Block]	'
	The Company has the following common stock equivalents for the six months ended June 30, 2013 and 2012, respectively:
		Six Months Ended June 30,
		2013			2012
	Stock options (exercise price - $425/share)		670			1,903
	Warrants (exercise price $4 – $1,275/share)		330,089			84,820
	Convertible debt (exercise price $17/share)		-			2,471
	Total common stock equivalents		330,759			89,194

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following at June 30, 2013 and December 31, 2012:
		As of June 30, 2013		As of December 31, 2012		Estimated Useful Life
	Furniture, fixtures and gym equipment	$	1,591,642	$	1,323,998	From 36 to 60 months
	Leasehold improvements		601,625		563,204	From 42 to 66 months
	Vehicles		100,584		100,584	5 years
	Displays		32,057		32,057	5 years
	Website		11,462		11,462	3 years
	Total		2,337,370		2,031,305
	Less: Accumulated depreciation and amortization		-1,008,323		-674,941
		$	1,329,047	$	1,356,364

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2013
Debt Disclosure [Abstract]	'
Schedule Of Long Term Debt [Table Text Block]	'
	At June 30, 2013 and December 31, 2012, debt consists of the following:
		As of June 30, 2013			As of December 31, 2012
	Auto loan - secured	$	9,729			15,380
	Unsecured debt		64,600			4,452,183
	Less: debt discount		-			-
	Unsecured debt - net		64,600			4,452,183
	Total debt		74,329			4,467,563
	Less: current portion		-74,329			-4,463,040
	Long term debt	$	-		$	4,523
Schedule Of Future Annual Principal Payments Of Debt [Table Text Block]	'
	Future annual principal payments for the above debt is as follows:
	Years Ending December 31,
	2013 (6 months)	$	70,840
	2014		3,489
	Total annual principal payments	$	74,329
Schedule Of Secured Debt Terms And Activity [Table Text Block]	'
	During the year ended December 31, 2012, the Company issued convertible debt totaling $519,950. The convertible debt includes the following terms:
				Year Ended
				December 31, 2012
				Amount of
				Principal Raised
	Interest Rate				8% - 10%
	Default interest rate				0% - 20%
	Maturity				January 3, 2012 to October 11, 2014
	Conversion terms 1	62% of lowest trade price for the last 7 trading days			100,000
	Conversion terms 2	65% of the lowest trade price in the 30 trading days previous to the conversion			19,950
	Conversion terms 3	35% multiplied by the average of the lowest three (3) trading prices (as defined below) for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date.			400,000
				$	519,950
Schedule Of Unsecured Debt Activity and Terms [Table Text Block]	'
	Unsecured debt consisted of the following activity and terms:
	Balance - December 31, 2012	$	4,452,183
	Repayments		-4,387,583
	Balance – June 30, 2013	$	64,600
Schedule Of Auto Loan Activity and Terms [Table Text Block]	'
	Vehicle loan account consisted of the following activity and terms:
					Interest Rate			Maturity
	Balance - December 31, 2012	$	15,380			6.99	%		26 payments of $1,008
	Repayments		-5,651
	Balance – June 30, 2013	$	9,729
Schedule Of Debt Issue Costs [Table Text Block]	'
	The following is a summary of the Company’s debt issue costs for the six months ended June 30, 2013 and year ended December 31, 2012 as follows:
		2013			2012
	Debt issue costs	$	335,433		$	851,923
	Accumulated amortization of debt issue costs		-335,433			-516,490
	Debt issue costs – net	$	-		$	335,433

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule Of Fair Value Of Derivative Instruments Conversion Feature [Table Text Block]	'
	The fair value of the conversion feature is summarized as follows:
	Derivative liability - December 31, 2012	$	-
	Fair value at the commitment date for equity instruments		8,175,459
	Fair value at the commitment date for warrants issued		96,913
	Fair value mark to market adjustment for equity instruments		5,716,688
	Fair value mark to market adjustment for warrants		55,275
	Conversion instruments exercised		-11,675,303
	Derivative liability – June 30, 2013	$	2,369,032
Schedule Of Derivative Liabilities Fair Value Assumptions At Commitment and Re-Measurement Date [Table Text Block]	'
	The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions:
		Commitment Date			Re-measurement Date
	Expected dividends		0	%		0	%
	Expected volatility		118% - 123	%		107	%
	Expected term:		1 year			17 months – 1 year
	Risk free interest rate		0.14% - 0.15%			0.15	%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders Equity [Table Text Block]	'
	During the six months ended June 30, 2013, the Company issued the following common stock:
	Transaction Type	Quantity			Valuation				Range of Value
		(#)			($)				per Share
									($)
	Conversion of Series D preferred stock to common stock		2,710,000			11,675,481			2.80 – 7.54
	Cash and warrants		953,236			8,059,330			8.26 – 9.32
	Executive/Board of Director compensation		62,289			264,879			3.48 – 6.00
	Stock issued for services and to settle liabilities		1,262,830			9,894,844			4.02 – 12.99
	Total		4,988,355			29,894,534			2.80 – 12.99
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The Black-Scholes assumptions used when the options were issued in the year ended December 31, 2010 are as follows:
	Exercise price	$	425
	Expected dividends		0	%
	Expected volatility		74.8	%
	Risk fee interest rate		1.4	%
	Expected life of option		5 years
	Expected forfeiture		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following is a summary of the Company’s stock option activity:
		Options			Weighted Average			Weighted Average		Aggregate Intrinsic
					Exercise Price			Remaining		Value
								Contractual Life
	Balance – December 31, 2012		1,847		$	425		2.25 years			-
	Granted		-
	Exercised		-
	Forfeited/Cancelled		-1,177		$	425
	Balance – June 30, 2013 – outstanding		670		$	425		1.75 years			-
	Balance – June 30, 2013 – exercisable		670		$	425		1.75 years			-
	Outstanding options held by related parties – 2013		-
	Exercisable options held by related parties – 2013		-
Schedule Of Warrants Activity [Table Text Block]	'
	A summary of warrant activity for the Company for the six months ended June 30, 2013 is as follows:
		Number of Warrants			Weighted Average Exercise Price
	Outstanding – December 31, 2012		89		$	1,275
	Granted		3,040,000			4.09
	Exercised		-2,710,000			4
	Balance as June 30, 2013		330,089		$	5.13
	Warrants Outstanding											Warrants Exercisable
	Range of			Number			Weighted Average			Weighted Average		Number		Weighted		Intrinsic Value
	Exercise Prices			Outstanding			Remaining			Exercise Price		Exercisable		Average
							Contractual Life (in							Exercise Price
							years)
		$4 - $1,275			330,089			0.95		$	5.13		330,089	$	5.13		1,340,000

Committments_Contingencies_and1

Committments, Contingencies and Other Matters (Tables)	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum annual lease payments for the above leases are approximately as follows:
	Years Ending December 31,
	2013 (6 months)	$	246,608
	2014		556,868
	2015		391,069
	2016		79,860
	2017		19,965
	Total minimum lease payments	$	1,294,370

Subsequent_Events_Tables

Subsequent Events (Tables)	6 Months Ended
	Jun. 30, 2013
Subsequent Events [Abstract]	'
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
	The Board approved Restricted Stock grants of the Company’s common stock in the aggregate amount of 1,550,000 shares including shares of the Company’s restricted stock to the following named executive officers and directors in the following amounts:
	Name	Title	Number of Shares of Restricted Stock
	Brad J. Pyatt	Co-Chairman, CEO and President		350,000
	L. Gary Davis	Chief Financial Officer		200,000
	John H. Bluher	Co-Chairman and Executive Vice President		150,000
	Richard Estalella	Chief Operating Officer		100,000
	Jeremy R. DeLuca	Executive Vice President – Chief Marketing Officer		225,000
	Cory J. Gregory	Executive Vice President		150,000
	Michael Doron	Director		25,000
	James Greenwell	Director		25,000
	Donald W. Prosser	Director		25,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Accounts receivable	$10,492,646	$4,416,193
Less: allowance for discounts	-1,004,000	-1,088,720
Less: allowance for doubtful accounts	-253,552	-25,129
Accounts receivable - net	$9,235,094	$3,302,344

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	Jun. 30, 2013	Dec. 31, 2012
Customer A [Member]	'	'
Concentration Percentage Of Accounts Receivable With Customers	14.00%	19.00%
Customer B [Member]	'	'
Concentration Percentage Of Accounts Receivable With Customers	8.00%	6.00%
Customer C [Member]	'	'
Concentration Percentage Of Accounts Receivable With Customers	7.00%	0.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Derivative liabilities (Level 2)	$2,369,032	$0

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 3) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Sales	$28,515,483	$18,869,103	$53,439,519	$38,171,872
Discounts	-3,035,424	-3,439,763	-5,398,293	-6,181,852
Sales - Net	$25,480,059	$15,429,340	$48,041,226	$31,990,020

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 4)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Customer A [Member]	'	'	'	'
Concentration percentage of revenue with customers	25.00%	33.00%	29.00%	40.00%
Customer B [Member]	'	'	'	'
Concentration percentage of revenue with customers	11.00%	8.00%	11.00%	11.00%
Customer C [Member]	'	'	'	'
Concentration percentage of revenue with customers	6.00%	1.00%	6.00%	17.00%

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 5) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Advertising	$3,275,200	$2,044,005	$5,592,577	$3,976,840

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details 6)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Total common stock equivalents	330,759	89,194
Employee Stock Option [Member]	'	'
Total common stock equivalents	670	1,903
Warrant [Member]	'	'
Total common stock equivalents	330,089	84,820
Convertible Debt [Member]	'	'
Total common stock equivalents	0	2,471

Recovered_Sheet1

Summary of Significant Accounting Policies (Details Textual) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended
	31-May-11	Jun. 30, 2013	Jun. 30, 2013	Dec. 31, 2012
Accounts payable and accrued liabilities	'	$8,173,356	$8,173,356	$11,721,205
Shipping and Handling Description	'	'	'Until March 1, 2013 MusclePharm used a manufacturer from Tennessee to ship directly to our customers, and after that date MusclePharm took control of the shipping and began shipping product to our customers from a previously leased 152,000 square foot distribution center in Franklin, Tennessee in close proximity of our manufacturer.	'
Percentage Of Royalty Based Net Income	10.00%	'	'	'
License Costs	250,000	'	'	'
Stock Option Exercised Price Per Share (in dollars per share)	'	'	$425	'
Minimum Warrants Exercised Price Per Share (in dollars per share)	'	'	$4	'
Maximum Warrants Exercised Price Per Share (in dollars per share)	'	'	$1,275	'
Maximum Convertible Debt Exercised Price Per Share (in dollars per share)	'	'	$17	'
Percentage Of Total Revenue	'	'	3.00%	'
Interest Expense, Debt	'	349	'	'
Derivative, Gain on Derivative	'	9,449,050	'	'
Incremental Warrants Attributable To Conversion Of Debt Securities	'	625,028	'	'
Manufacturer [Member]	'	'	'	'
Accounts payable and accrued liabilities	'	$4,213,394	$4,213,394	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Furniture, fixtures and gym equipment	$1,591,642	$1,323,998
Leasehold improvements	601,625	563,204
Total	2,337,370	2,031,305
Less: Accumulated depreciation and amortization	-1,008,323	-674,941
Property, Plant and Equipment, Net	1,329,047	1,356,364
Furniture and Fixtures [Member]	'	'
Estimated Useful Life	'From 36 to 60 months	'
Leasehold Improvements [Member]	'	'
Estimated Useful Life	'From 42 to 66 months	'
Vehicles [Member]	'	'
Property, Plant and Equipment, Other, Gross	100,584	100,584
Property, Plant and Equipment, Useful Life (in years)	'5 years	'
Displays [Member]	'	'
Property, Plant and Equipment, Other, Gross	32,057	32,057
Property, Plant and Equipment, Useful Life (in years)	'5 years	'
Website [Member]	'	'
Property, Plant and Equipment, Other, Gross	$11,462	$11,462
Property, Plant and Equipment, Useful Life (in years)	'3 years	'

Debt_Details

Debt (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Unsecured debt	$64,600	$4,452,183
Less: debt discount	0	0
Unsecured debt - net	64,600	4,452,183
Total debt	74,329	4,467,563
Less: current portion	-74,329	-4,463,040
Long term debt	0	4,523
Auto Loan [Member]	'	'
Auto loan - secured	$9,729	$15,380

Debt_Details_1

Debt (Details 1) (USD $)	Jun. 30, 2013
2013 (6 months)	$70,840
2014	3,489
Total annual principal payments	$74,329

Debt_Details_2

Debt (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2012
Conversion Terms One [Member]	'
Proceeds from Convertible Debt	$100,000
Description Of Convertible Debt Secured Derivative Liabilities	'62% of lowest trade price for the last 7 trading days
Conversion Terms Two [Member]	'
Proceeds from Convertible Debt	19,950
Description Of Convertible Debt Secured Derivative Liabilities	'65% of the lowest trade price in the 30 trading days previous to the conversion
Conversion Terms Three [Member]	'
Proceeds from Convertible Debt	400,000
Description Of Convertible Debt Secured Derivative Liabilities	'35% multiplied by the average of the lowest three (3) trading prices (as defined below) for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date.
Convertible Debt [Member]	'
Maturity	'January 3, 2012 to October 11, 2014
Proceeds from Convertible Debt	$519,950
Maximum [Member] | Convertible Debt [Member]	'
Interest Rate	10.00%
Default interest rate	20.00%
Minimum [Member] | Convertible Debt [Member]	'
Interest Rate	8.00%
Default interest rate	0.00%

Debt_Details_3

Debt (Details 3) (USD $)	6 Months Ended
	Jun. 30, 2013
Balance - December 31, 2012	$4,452,183
Repayments	-4,387,583
Balance - june 30, 2013	$64,600

Debt_Details_4

Debt (Details 4) (Vehicle Loan [Member], USD $)	6 Months Ended
	Jun. 30, 2013
Vehicle Loan [Member]	'
Balance - December 31, 2012	$15,380
Repayments	-5,651
Balance - june 30, 2013	$9,729
Interest Rate	6.99%
Maturity	'26 payments of $1,008

Debt_Details_5

Debt (Details 5) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Debt issue costs	$335,433	$851,923
Accumulated amortization of debt issue costs	-335,433	-516,490
Debt issue costs - net	$0	$335,433

Debt_Details_Textual

Debt (Details Textual) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Debt Default, Short-term Debt, Amount	$64,600	'	$64,600
Debt Conversion, Converted Instrument, Shares Issued (in shares)	'	'	519,950
Debt issue costs	0	-106,950	'
Amortization of debt issue costs	335,433	184,031	'
Warrants Purchase Common Stock	'	'	22,633
Warrants issued in conjunction with debt issue costs	'	'	$427,759

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	6 Months Ended
	Jun. 30, 2013
Derivative liability - December 31, 2012	$0
Fair value at the commitment date for equity instruments	8,175,459
Fair value at the commitment date for warrants issued	96,913
Fair value mark to market adjustment for equity instruments	5,716,688
Fair value mark to market adjustment for warrants	55,275
Conversion instruments exercised	-11,675,303
Derivative liability - June 30, 2013	$2,369,032

Derivative_Liabilities_Details1

Derivative Liabilities (Details 1)	6 Months Ended
	Jun. 30, 2013
Commitment Date [Member]	'
Expected dividends	0.00%
Expected term:	'1 year
Commitment Date [Member] | Maximum [Member]	'
Expected volatility	123.00%
Risk free interest rate	0.15%
Commitment Date [Member] | Minimum [Member]	'
Expected volatility	118.00%
Risk free interest rate	0.14%
Re Measurement Date [Member]	'
Expected dividends	0.00%
Expected volatility	107.00%
Risk free interest rate	0.15%
Re Measurement Date [Member] | Maximum [Member]	'
Expected term:	'1 year
Re Measurement Date [Member] | Minimum [Member]	'
Expected term:	'17 months

Derivative_Liabilities_Details2

Derivative Liabilities (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Derivative expense	$0	$1,029,541	$96,913	$2,486,451

Restricted_Stock_Units_Details

Restricted Stock Units (Details Textual) (USD $)	1 Months Ended	6 Months Ended
	Nov. 30, 2012	Jun. 30, 2013
Stock Issued During Period, Shares, Issued For Services (in shares)	'	1,262,830
Stock Issued During Period, Value, Issued For Services	'	$9,894,844
Chief Operating Officer [Member]	'	'
Stock Issued During Period, Shares, Issued For Services (in shares)	70,589	'
Stock Issued During Period, Value, Issued For Services	245,400	'
Shares Vesting In Next Twelve Months Number	'	23,529
Shares Vesting In Year One Number	'	23,530
Shares Vesting In Year Two Number	'	23,530
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	'	23,529
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	123,036
Chief Financial Officer [Member]	'	'
Stock Issued During Period, Shares, Issued For Services (in shares)	58,824	'
Stock Issued During Period, Value, Issued For Services	204,500	'
Shares Vesting In Next Twelve Months Number	'	19,608
Shares Vesting In Year One Number	'	19,608
Shares Vesting In Year Two Number	'	19,608
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	$102,530

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	6 Months Ended
	Jun. 30, 2013
Conversion of Series D preferred stock to common stock, Quantity	2,710,000
Cash and warrants, Quantity	953,236
Executive/Board of Director compensation, Quantity	62,289
Stock issued for services and to settle liabilities, Quantity	1,262,830
Total, Quantity	4,988,355
Conversion of Series D Preferred Stock to common stock, Valuation	$11,675,481
Cash and warrants, Valuation	8,059,330
Executive/Board of Director compensation, Valuation	264,879
Stock issued for services and to settle liabilities, Valuation	9,894,844
Total, Valuation	$29,894,534
Minimum [Member]	'
Conversion of Series D Preferred Stock to common stock, Range of Value per share	$2.80
Cash and warrants, Range of Value per share	$8.26
Executive/Board of Director compensation, Range of Value per share	$3.48
Stock issued for services and to settle liabilities, Range of Value per Share	$4.02
Total, Range of Value per Share	$2.80
Maximum [Member]	'
Conversion of Series D Preferred Stock to common stock, Range of Value per share	$7.54
Cash and warrants, Range of Value per share	$9.32
Executive/Board of Director compensation, Range of Value per share	$6
Stock issued for services and to settle liabilities, Range of Value per Share	$12.99
Total, Range of Value per Share	$12.99

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2010
Exercise price	$425
Expected dividends	0.00%
Expected volatility	74.80%
Risk fee interest rate	1.40%
Expected life of option	'5 years
Expected forfeiture	0.00%

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Options Balance (in shares)	1,847	'
Options Granted (in shares)	0	'
Options Exercised (in shares)	0	'
Options Forfeited/Cancelled (in shares)	-1,177	'
Options Balance, outstanding (in shares)	670	1,847
Options exercisable, (in shares)	670	'
Outstanding options held by related parties	0	'
Exercisable options held by related parties	0	'
Weighted Average Exercise Price Balance (in dollars per share)	$425	'
Weighted Average Exercise Price Forfeited/Cancelled (in dollars per share)	$425	'
Weighted Average Exercise Price Balance, outstanding (in dollars per share)	$425	$425
Weighted Average Exercise Price exercisable (in dollars per share)	$425	'
Balance, Weighted Average Remaining Contractual Life	'1 year 9 months	'2 years 3 months
Weighted Average Remaining Contractual Life exercisable (years)	'1 year 9 months	'
Aggregate Intrinsic Value, Balance	$0	$0
Aggregate Intrinsic Value exercisable	0	'
Aggregate Intrinsic Value, Balance, Outstanding	$0	'

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013
	Minimum [Member]	Maximum [Member]	Warrant [Member]
Number of Warrants, Outstanding Balance (in shares)	'	'	89
Number of Warrants, Granted (in shares)	'	'	3,040,000
Number of Warrants, Exercised (in shares)	'	'	-2,710,000
Number of Warrants, Outstanding Balance (in shares)	'	'	330,089
Weighted Average Exercise Price, Balance (in dollars per share)	$4	$1,275	$1,275
Weighted Average Exercise Price, Granted (in dollars per share)	'	'	$4.09
Weighted Average Exercise Price, Exercised (in dollars per share)	'	'	$4
Weighted Average Exercise Price, Balance (in dollars per share)	$4	$1,275	$5.13
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	'	'	'11 months 12 days
Warrants Exercisable, Numbers Exercisable (in shares)	'	'	330,089
Warrants Exercisable, Weighted Average Exercise Price (in dollars per share)	'	'	$5.13
Warrants Exercisable, Intrinsic Value	'	'	$1,340,000
Warrant Outstanding Weighted Average Exercise Price	'	'	$5.13
Warrant Outstanding Number Outstanding	'	'	330,089

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

Feb. 04, 2013

Nov. 30, 2012

Oct. 31, 2011

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Nov. 30, 2012

Jun. 30, 2013

Jul. 31, 2012

Jun. 30, 2013

Jun. 30, 2013

Nov. 30, 2012

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Nov. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Aug. 31, 2011

Jun. 30, 2013

Jun. 30, 2012

Aug. 01, 2011

Oct. 31, 2011

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jan. 02, 2013

Jun. 30, 2012

Grq Amended Agreement [Member]

Grq Amended Agreement [Member]

Grq [Member]

Grq [Member]

Grq [Member]

Melechdavid [Member]

Melechdavid [Member]

Commitment Date [Member]

Re Measurement Date [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Description Of Class Of Stock Provision

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'This class of stock has the following provisions: Non-voting, No rights to dividends, No liquidation value, and Convertible into 200 shares of common stock.

'

'

'This class of stock has the following provisions: Voting rights entitling the holders to an aggregate 51% voting control, No rights to dividends, Stated value of $0.001 per share, Liquidation rights entitle the receipt of net assets on a pro-rata basis with the holders of our common stock; and Non-convertible.

'

'

'

'This class of stock has the following provisions: Stated Value - $1,000 per share, Non-voting, Liquidation rights entitle an amount equal to the stated value, plus any accrued and unpaid dividends, As long as any Series C, Convertible Preferred Stock is outstanding, the Company is prohibited from executing various corporate actions without the majority consent of the holders of Series C, Convertible Preferred Stockholders authorization; and Convertible at the higher of (a) $0.01 or (b) such price that is a 50% discount to market using the average of the low two closing bid prices, five days preceding conversion.

'

'

'The shares of Series D have the following provisions: Voting rights based on number of common shares of conversion option; Initially no rights to dividends; Liquidation rights entitle an amount equal to the stated value, plus any accrued and unpaid dividends, Convertible into 2 shares of common stock, subject to adjustment.

'

'

Stockholders' Equity, Reverse Stock Split

'

'On November 26, 2012, the Company (i) effected a 1-for-850 reverse stock split of our common stock, including a proportionate reduction in the number of authorized shares of our common stock from 2.36 billion shares to 2.8 million shares of common stock, and (ii) amended our articles of incorporation to increase the number of authorized shares of common stock (post reverse stock split) from 2,941,177 to 100 million effective November 27, 2012.

'

'

'

'1-for-850

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued to settle accounts payable and due to factor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$190,000

'

'

'

'

'

Stock Issued During Period Shares New Issues For Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

'

'

Stock Issued During Period Value New Issues For Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

Stock Issued During Period Price Per Share For Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

Stock Issued During Period Shares New Issues For Services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

90

'

'

'

'

'

Stock Issued During Period Value New Issues For Services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

90,000

'

'

'

'

'

Stock Issued During Period Price Per Share For Services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

Conversion to common stock

'

'

22,353

'

'

22,353

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

190

'

'

'

'

'

Stock Issued During Period Shares Conversion Of Convertible Securities Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

Stock Issued During Period Shares Conversion Of Convertible Securities Loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

614,984

'

'

'

'

'

Derivative expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

293

175

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Shares Issuable Upon Conversion Of Warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

Conversion Of Warrants To Purchase Shares

'

'

'

1,500,000

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Repurchased During Period, Shares

'

'

'

'

'

18,825

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Repurchased During Period, Value

'

'

'

'

'

260,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Repurchased During Period Per Share

'

'

'

'

'

$5.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

5,000,000

'

51

51

51

'

500

500

1,600,000

1,600,000

1,600,000

Number Of Shares Sold Under Subscription Agreement

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain Loss On Repurchase Of Common Stock

'

'

'

'

'

156,463

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Preferred Stock and Preference Stock

'

'

'

'

'

12,000,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

190

'

'

'

'

'

Date Of Agreement

'

'

'

'

'

'

'

'

2-Apr-13

19-Jul-12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Outstanding Common Stock

'

'

'

'

'

'

'

'

'

4.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

'

'

'

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum Shares Under Agreement

'

'

'

'

'

'

'

420,000

'

'

'

'

570,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Issued Under Agreement

'

'

'

'

'

'

'

'

305,889

'

'

35,359

'

341,247

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional Shares Issued Under Agreement

'

'

'

'

'

'

'

'

78,753

'

'

'

'

228,753

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Diluted Equity Shares

'

'

'

'

'

'

'

'

'

4.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consulting Agreement Term

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

General and Administrative Expense

'

'

'

$10,654,272

$4,151,076

$19,540,512

$8,543,887

'

'

'

$3,037,636

'

'

$6,591,816

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Committments_Contingencies_and2

Committments, Contingencies and Other Matters (Details) (USD $)	Jun. 30, 2013
Years Ending Dec. 31	'
2013 (6 months)	$246,608
2014	556,868
2015	391,069
2016	79,860
2017	19,965
Total minimum lease payments	$1,294,370

Committments_Contingencies_and3

Committments, Contingencies and Other Matters (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Operating Lease Expire Term	'2017	'
Operating Leases, Rent Expense, Net	$298,887	$117,247
Accrued Payroll Taxes	87,339	'
Product Liability Insurance Deduction	10,000	'
Aggregate Product Liability Retained Loss	$5,000,000	'

Defined_Contribution_Plan_Deta

Defined Contribution Plan (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Noncash Contribution Expense	'	$17,000
Defined Contribution Plan, Employer Discretionary Contribution Amount	$28,530	$18,251

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (Chief Financial Officer [Member])	6 Months Ended
	Jun. 30, 2013
Chief Financial Officer [Member]	'
Percentage Of Equity Interest	1.75%

Subsequent_Events_Details

Subsequent Events (Details)	6 Months Ended
	Jun. 30, 2013
Brad J. Pyatt [Member] | Co-Chairman, CEO and President [Member]	'
Number of Shares of Restricted Stock	350,000
L Gary Davis [Member] | Chief Financial Officer [Member]	'
Number of Shares of Restricted Stock	200,000
John H. Bluher [Member] | Co-Chairman and Executive Vice President [Member]	'
Number of Shares of Restricted Stock	150,000
Richard Estalella [Member] | Chief Operating Officer [Member]	'
Number of Shares of Restricted Stock	100,000
Jeremy R. DeLuca [Member] | Chief Marketing Officer [Member]	'
Number of Shares of Restricted Stock	225,000
Cory J. Gregory [Member] | Executive Vice President [Member]	'
Number of Shares of Restricted Stock	150,000
Michael Doron [Member] | Director [Member]	'
Number of Shares of Restricted Stock	25,000
James Greenwell [Member] | Director [Member]	'
Number of Shares of Restricted Stock	25,000
Donald W. Prosser [Member] | Director [Member]	'
Number of Shares of Restricted Stock	25,000

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	6 Months Ended			0 Months Ended	6 Months Ended		1 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Aug. 06, 2013	Aug. 09, 2013	Jun. 30, 2013	Jun. 30, 2013	Jul. 31, 2013
		Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Marine MP LLC [Member]
			Director [Member]	Private Placement [Member]	December 31, 2013 [Member]	December 31, 2015 [Member]	Subsequent Event [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross	$17,065,500	$1,550,000	'	'	'	'	'
Restricted stock agreement grant vesting percentage	'	'	'	'	17.00%	83.00%	'
Other Inventory, Purchased Goods, Gross	'	4,664,421	'	'	'	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	'	'	'	'	'	'	780,000
Stock Issued During Period, Shares, New Issues	'	'	'	238,096	'	'	'
Sale of Stock, Price Per Share	'	'	'	$10.50	'	'	'
Amount Involved In Corporate Officer Changes	'	'	120,000	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	'	$2,500,000	'	'	'